**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 50-year-old man developed relapse of coronavirus disease-2019 (COVID-19) following misuse of prednisolone for sarcoidosis.

The man was initially diagnosed with Lofgren syndrome (sarcoidosis) presenting as bilateral ankle joint swelling, cough and mediastinal lymphadenopathy in January 2019. Hence, he had received treatment with prednisolone until October 2019, which resulted in complete resolution of the symptoms. On 12 March 2020, he had a contact with a severe acute respiratory syndrome-related coronavirus (SARS-CoV-2) positive patient. One week after the initial contact, he developed dry cough and fever indicative of COVID-19 infection. Additionally, he also experienced ankle pain at night and with exercise. Four days later, COVID-19 infection improved with resolution of fever, while joint complaints persisted. Fourteen days after the initial contact with Covid-19 infected patient, his SARS-CoV-2 RNA test showed negative results. However, his swelling and pain in both ankles persisted. Hence, on 28 March 2020, he re-started therapy with prednisolone at doses of 20−30 mg/day \[*route not stated*\] against medical advice (drug misuse). On 2 April 2020 (five days after the initiation of prednisolone), he was hospitalised with a slight right ankle swelling and painful ankles. Auscultation showed minor rales in two-thirds of the right lung. Laboratory tests showed elevated leucocytes and neutrophils count with the borderline elevation of angiotensin-converting enzyme (ACE). His soluble interleukin-2 receptor and CRP levels were normal. An unenhanced chest CT scan showed peripheral, bilateral and ill-defined ground-glass opacities in the right lower lobe. Additionally, consolidations observed in the right peripheral lung base and left lower lobe. No typical signs of alveolar sarcoidosis-like peribronchovascular consolidations were present. His mediastinal lymph nodes were normal in size. Subsequently, a radiologist confirmed CT findings as highly suspected for Covid-19 pneumonia. His repeat SARS-CoV-2 RNA test was weakly positive for a nasopharyngeal swab, while clearly positive with the oral swab. It was considered that, the initial test might be false negative, and after initiation of prednisolone, he developed a relapse of COVID-19 infection with COVID-19-induced pneumonia.

Within 2 days, prednisolone was stopped, and the man started receiving off-label treatment with oral hydroxychloroquine 400 mg/day. He had no adverse event during a course of infection, and he was discharged after a negative SARS-CoV2 RNA test.
